Bayer: In the phase III prostate cancer trial, darotamide combined with androgen deprivation therapy and radiation therapy reduced the risk of metastasis or death by 58%.

Zhitongcaijing · 5d ago
Bayer: In the phase III prostate cancer trial, darotamide combined with androgen deprivation therapy and radiation therapy reduced the risk of metastasis or death by 58%.